INS and Hypoglycemia: Such a profile more closely mimics endogenous postprandialinsulin kinetics and therefore offers a safer pharmacodynamic response.By preventing sudden spikes in peripheral insulin exposure, the casNP/insulin/C10 formulation avoids the exaggerated glucose uptake by muscleand adipose tissue that can lead to hypoglycemia after s.c. IAsp administration.This distinction, fast hepatic engagement followed by more gradualperipheral exposure, represents a major therapeutic advantage of theoral route, providing a more physiological and safer insulin profile.,